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Abstract 
Purpose: Expression of p95HER2 (p95), a truncated form of the HER2 receptor, which lacks the 
trastuzumab binding site but retains kinase activity, has been reported as a prognostic biomarker 
for poor outcomes in trastuzumab-treated HER2-positive metastatic breast cancer. The impact of 
p95 expression on trastuzumab treatment efficacy in early HER2-positive breast cancer is less 
clear. In the current study, p95 was tested as a predictive marker of trastuzumab treatment 
benefit in the HER2-positive subset of the FinHer adjuvant phase III trial. 
Experimental Design: In the FinHer trial, 232 HER2-positive early breast cancer patients were 
randomized to receive chemotherapy plus 9-weeks of trastuzumab or no trastuzumab treatment. 
Quantitative p95 protein expression was measured in formalin-fixed paraffin-embedded samples 
using the p95 VeraTag
®
 assay (Monogram Biosciences), specific for the M611 form of p95. 
Quantitative HER2 protein expression was measured using the HERmark
®
 assay (Monogram 
Biosciences). Distant disease-free survival (DDFS) was used as the primary outcome measure. 
Results: In the arm receiving chemotherapy only, increasing log10(p95) correlated with shorter 
DDFS (HR=2.0; P=.02). In the arm receiving chemotherapy plus trastuzumab (N=95), increasing 
log10(p95) was not correlated with a shorter DDFS. In a combined analysis of both treatment 
arms, high breast tumor p95 content was significantly correlated with trastuzumab treatment 
benefit in multivariate models (interaction P=.01). 
Conclusions: p95 expression levels were prognostic in the chemotherapy-alone arm and 
predictive of trastuzumab treatment benefit in FinHer. These results warrant further investigation 
of p95 as a predictive marker of trastuzumab treatment benefit in the adjuvant setting. 
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Statement of translational relevance:  Elevated expression of p95HER2, the M611 carboxy-
terminal fragment (CTF) of HER2, is a prognostic indicator of poor outcome in metastatic breast 
cancer. Measurement of p95HER2 in the FinHer adjuvant clinical trial provided the first 
evidence of the predictive power of p95HER2 comparing a trastuzumab-treated group vs. a 
control group not treated with trastuzumab. In the adjuvant setting, elevated p95HER2 
expression is prognostic for poor outcomes in the absence of trastuzumab treatment and is 
predictive of favorable outcomes in response to chemotherapy plus trastuzumab treatment. 
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Introduction 
p95HER2 (p95) is a truncated form of the HER2 receptor which lacks the extracellular 
domain and binding sites for trastuzumab and pertuzumab. Although several carboxy-terminal 
fragments (CTF) of HER2 have been described, the form with methionine 611 at its N-terminus 
(M611CTF) appears to be the most biologically relevant [1, 2], which is attributable to the 
covalent homodimerization of unpaired cysteines near the N-terminus. M611CTF enhances cell 
migration and invasion [3, 4], is more potent than full-length HER2 in supporting tumor 
formation [2, 3], promotes metastasis [5] and reduces estrogen receptor expression [6], 
potentially reducing the effectiveness of anti-estrogen therapies. 
p95 is prognostic for poor outcome in HER2-positive patients receiving trastuzumab-based 
therapy in the metastatic setting [7-11].  However, p95 expression can enhance sensitivity to 
chemotherapy in vitro and in patient-derived xenograft models [12], raising the possibility that 
high p95 expression may be predictive of better outcomes in patients receiving concurrent 
chemotherapy and trastuzumab therapy in the adjuvant setting prior to chemotherapy resistance. 
In fact, in the neoadjuvant NeoALTTO trial, increasing p95 expression correlated with better 
pathological complete response (pCR) in the trastuzumab + chemotherapy arm, although this 
was attributed to higher HER2 expression in tumors expressing high p95 levels [13]. 
The clinical significance of breast tumor p95 expression is not well-defined in early breast 
cancer. The goal of the current study was to determine whether p95 is a predictive biomarker of 
treatment benefit for trastuzumab plus chemotherapy in the adjuvant setting among HER2-
positive cancer patients within the FinHer phase III clinical trial [14, 15]. To our knowledge, this 
is the first study to correlate p95 expression with the degree of benefit of adding trastuzumab to 
chemotherapy in early breast cancer. 
5 
Materials and Methods 
Patients 
The results of the FinHer trial (ISRCTN76560285) have been reported previously [14, 15]. 
Briefly, 1,010 women diagnosed with early breast cancer were randomized to three 21-day 
cycles of either docetaxel or vinorelbine followed by three 21-day cycles of fluorouracil, 
epirubicin and cyclophosphamide. Those with HER2-positive disease as determined by 
immunohistochemistry (IHC) and confirmed by chromogenic in situ hybridization (CISH) were 
randomized to receive or not receive 9 weeks of trastuzumab. Chemotherapy arms were 
combined for the current analysis, but chemotherapy type was included either by stratification or 
as an independent variable. Out of the 232 patients who had HER2-positive cancer, 192 (82.8%) 
had sufficient formalin-fixed paraffin-embedded (FFPE) breast tumor tissue to measure HER2 
and p95, and were included in the analysis (Table 1 and Figure S1). The set of 192 cases is likely 
an unbiased representation of the entire set since the remaining 40 cases were not included only 
because sufficient tissue was not available for testing. Final follow up for distant disease-free 
survival (DDFS) was used as the outcome measure [15]. The study protocol was approved by an 
Institutional Review Board (an ethics committee) of the Helsinki University Hospital 
(HUS113/13/03/02/09). The FinHer trial participants provided written informed consent before 
study entry. 
Quantitative HER2 Measurements 
HER2 protein expression was quantified using the HERmark assay, a CLIA/CAP validated 
assay performed in a clinical reference laboratory (Monogram Biosciences, South San Francisco, 
CA), as described previously [16-18]. Two HER2 antibodies bound to the same HER2 molecule 
enable the release of a fluorescent tag that is quantified by capillary electrophoresis [18]. In 
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capillary electrophoresis, the fluorescence of the released tag from the tumor is compared to the 
fluorescence of an internal standard, and their ratio (relative fluorescence, RF) is then normalized 
to the tumor area in the FFPE sample to generate units of RF/mm
2
. The HERmark results in units
of RF/mm
2
 are proportional to the protein content targeted with the antibodies in the sample.
Multiple cell line controls were included in each batch as standards for batch-to-batch 
normalization. Analytical cutoffs aligned to central HER2 determination were determined prior 
to the current study to define HERmark negative values (HER2 < 10.5 RF/mm
2
) and HERmark
positive values (HER2 > 17.8 RF/mm
2
) with equivocal values defined as 10.5 RF/mm
2 ≤ HER2
≤ 17.8 RF/mm2 (supplementary Figure S2). These cutoffs were assigned based on the <5th
percentile of centrally determined HER2-positives and the >95th percentile of centrally 
determined HER2-negatives, respectively, based on a reference database of 1,090 breast cancer 
patient samples. An established clinical cutoff of 13.8 RF/mm
2 
that best discriminates favorable
versus unfavorable treatment outcomes for patients receiving trastuzumab-based therapy [19] 
was used in all clinical analyses in the current study to define HER2-positivity by the HERmark 
assay. 
Quantitative p95 Measurements 
The VeraTag p95 assay, which utilizes the proprietary clone D9 p95 monoclonal antibody 
was previously described [8]. D9 specifically recognizes the highly active M611-HER2-CTF 
form of truncated HER2. Steric interference likely blocks D9 binding to full length HER2 [8]. 
D9 binding of p95 in formalin-fixed paraffin-embedded (FFPE) tumor sections was detected by a 
secondary antibody conjugated to a fluorescent VeraTag reporter molecule by a disulfide 
linkage. The VeraTag reporter was released by disulfide reduction and quantified by capillary 
electrophoresis. Similar to the HERmark assay, RF was normalized to tumor area to generate 
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units of RF/mm
2
. Multiple reference cell lines were evaluated within each assay batch to enable
batch-to-batch normalization. A pre-specified p95 ≥ 2.8 RF/mm2 cutoff, derived from an
independent training set [8] and verified in an independent validation set [9], was used to define 
p95-positivity in the current study. 
Statistical Methods 
The Mann-Whitney U test was used to calculate P-values for differences in distributions of 
p95 or HER2 in hormone receptor positive vs. negative subgroups. The Kaplan-Meier method 
and Cox proportional hazards models were used to assess correlations of patient outcomes with 
HER2, p95 and other clinical variables. DDFS was used as the primary outcome measure, 
defined as the time period from the date of randomization to the date of first cancer recurrence 
outside of the ipsilateral locoregional region or to death whenever death occurred before distant 
recurrence, censoring patients who were alive without distant recurrence on their last follow-up 
date [15]. In Cox analyses with interaction terms including trastuzumab and either HER2 or p95, 
the hazard ratio for trastuzumab treatment was calculated at the median HER2 or p95 level by 
normalizing the HER2 and p95 values by their respective median. The predictive power of 
HER2 or p95 was determined by P < 0.05 of the biomarker-trastuzumab interaction term in a 
multivariate Cox model. 
Results 
p95HER and HER2 expression 
In all of the 192 cancers, HER2-positivity had been confirmed using CISH testing [15]. The 
fraction of HERmark HER2-negative patients was not statistically different (P = 0.29) from the 
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fraction of HER2 IHC 0 and 1+ patients as determined by central laboratory HER2 IHC retesting 
(Table 1). 
HER2 expression was higher in the steroid hormone receptor (HR)-negative subset (P = .01) 
as previously reported [20] (Figure 1a). p95 levels were also higher in the HR-negative subset (P 
< .001), consistent with previous reports [9] (Figure 1b). Correspondingly, the distribution of p95 
and HER2 for the HR-negative subset was shifted towards higher p95 and HER2, yielding 55% 
of patients above the p95 cutoff for HR-negative patients versus 32% for HR-positive patients 
(Figure 1c and 1d). For the subset above the HERmark clinical cutoff, 60% of the HR-negative 
patients were above the p95 cutoff, and 38% of the HR-positive patients were above the p95 
cutoff. A weak correlation was observed between log10(p95) and log10(HER2) values (R
2
 = 0.28;
P < .001). This correlation was stronger in the HR-positive subset (R
2
 = 0.38; P < .001) than in
the HR-negative subset (R
2
 = 0.14; P < .001).
Prognostic correlation of HER2 and p95 with DDFS 
Correlations of HER2 and p95 expression levels with DDFS in the subsets of patients who 
were treated with chemotherapy alone versus chemotherapy plus trastuzumab were examined 
using stratification based on hormone receptor status, nodal status and chemotherapy type (Table 
2). For these analyses, the two chemotherapy arms (docetaxel and vinorelbine) for each 
trastuzumab allocation group were combined. In the chemotherapy-only arms, tumor HER2 
content was not associated with DDFS (P = .30), while increasing p95 was correlated with 
shorter DDFS (HR = 2.0/log; P = .02). In the chemotherapy plus trastuzumab arms, neither 
HER2 (P = .93) nor p95 (P = .19) was associated with DDFS. The observation that p95 
correlated with DDFS in the absence of trastuzumab treatment, but not in the presence of 
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trastuzumab treatment, suggested that p95 expression levels may be predictive of the benefit of 
adding trastuzumab to chemotherapy. 
Predictive correlation of HER2 and p95 with trastuzumab benefit 
A test for biomarker-treatment interaction was performed for HER2 and p95 (Table 3) to 
determine whether HER2 or p95 expression was predictive of trastuzumab benefit. Important 
clinical variables were included in the multivariate models, including nodal status and hormone 
receptor status. Chemotherapy arm was also included as an independent variable. Breast tumor 
HER2 content was not predictive of trastuzumab benefit (P = .35); however, high tumor p95 
content was predictive of trastuzumab benefit (P = .01). 
Kaplan-Meier analysis was used to illustrate the difference in the hazard ratios of treatment 
arms with or without trastuzumab in the p95-negative and p95-positive subgroups (Figure 2). 
Patient groups with p95-negative tumors exhibited no differences in DDFS when treated with 
chemotherapy alone or chemotherapy plus trastuzumab (HR = 0.84; P = .66). In contrast, p95-
positive patient groups had the shortest DDFS in the absence of adjuvant trastuzumab treatment, 
yet received the most benefit from trastuzumab (HR = 0.32; P = .03). The results remained 
essentially similar when the time to any recurrence was used as the end point in place of DDFS 
(data not shown). 
The tests for interaction of trastuzumab with p95 were repeated with selected subsets of 
patients to determine which factors, if any, had the strongest influence on the predictive 
association of p95 with trastuzumab benefit. Separate interaction tests for hormone receptor 
negative and positive subsets demonstrated that a high breast cancer p95 content was highly 
predictive of trastuzumab benefit in the hormone receptor negative subset (P = .009) in contrast 
to the hormone receptor positive subset (P = .90) (Table 4). High p95 also appeared more 
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predictive of trastuzumab benefit in the docetaxel arm (P = .02) as opposed to the vinorelbine 
arm (P = .52) (Supplementary Table 1). 
Discussion 
p95 was first described as a correlate of known poor prognostic markers in breast cancer [21, 
22]. Gradually, the entity discovered as p95 was revealed to be a family of HER2 CTFs varying 
in length and oncogenic activity [1, 2, 23, 24]. Generally, HER2 CTF’s truncated below the 
transmembrane domain of HER2 are most abundant yet biologically inactive, while those 
retaining the transmembrane domain exhibit the most potent activity. Specific antibodies against 
M611CTF, the most potent HER2 CTF, have enabled specific detection of M611CTF in the 
background of abundant inactive CTF’s [6, 8]. 
The first clinical study to characterize p95 expression in breast cancer before the era of 
trastuzumab treatment found that high p95 expression was an indicator of poor prognosis, and 
that p95 expression was largely responsible for the poor prognosis associated with HER2 
overexpression [25]. Our observations reported here are consistent with these initial findings: 
p95 expression is prognostic for shorter DDFS in the arms receiving chemotherapy without 
trastuzumab, while HER2 expression is not correlated with DDFS (Table 2). 
Although p95 is a prognostic marker of poor outcome in trastuzumab-treated metastatic breast 
cancer [7-11], p95 can be a favorable prognostic marker in early breast cancer [13, 26]. This 
seemingly paradoxical finding may be related to sensitivity to chemotherapy [12] in early breast 
cancer that may be lost in previously treated metastatic breast cancer. In the current study, we 
only observed a weak trend supporting a correlation between increasing p95 expression and 
longer DDFS (HR = 0.58/log; P = .19), possibly due to the low event rate in the adjuvant setting. 
Interestingly, the predictive power of p95 expression may be dependent on the type of 
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chemotherapy administered concurrently with trastuzumab. P95 was predictive of trastuzumab 
benefit in the docetaxel-containing arms but not the vinorelbine-containing arms (Supplementary 
Table 1). However, this finding may be influenced by the reduced effectiveness of vinorebine as 
compared with docetaxel in combination with trastuzumab [15] or the smaller number of events 
in this subset analysis. 
The current study is the first test of p95 as a predictive marker of trastuzumab treatment 
benefit. The hypothesis that p95 may be predictive of trastuzumab benefit can be built on 
findings that p95 is a marker of poor prognosis in the absence of trastuzumab treatment [25] and 
that p95 may be a marker of increased pCR in trastuzumab-treated neo-adjuvant breast cancer 
[13, 26]. In the current study we found that high p95 expression is predictive of trastuzumab 
benefit in adjuvant breast cancer in a multivariable Cox model (Table 3) based on the significant 
interaction P-value (P = .01), while breast cancer HER2 content was not predictive (P = .30) in 
the present cohort of patients where all cancers were HER2-positive by CISH. 
HER2-directed tyrosine kinase inhibitors (TKI’s) can suppress p95-mediated signaling [7, 
27]. Lapatinib, a TKI that inhibits HER2 and HER1, is approved for the second line treatment of 
metastatic HER2-positive breast cancer following a trastuzumab-containing treatment. More 
recently, second line lapatinib use was found inferior to trastuzumab emtansine (T-DM1) [28], 
likely relegating lapatinib to third line treatment. Although the NeoALTTO study showed a 
benefit of adding lapatinib to trastuzumab in the neoadjuvant setting [29], some other Phase III 
neoadjuvant trials reported only non-significant trends toward benefit with the combination [30, 
31, 32]. In the ALTTO adjuvant trial, there was a non-significant trend supporting the benefit of 
adding lapatinib to trastuzumab [33]. Taken together, these trial results suggest that HER2-
targeting TKI’s might be most effective when used in a selected subset of the HER2-positive 
breast cancer patients. To this end, we have identified a subset of HER2-positive breast cancer 
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with high p95 expression that exhibited the most benefit from trastuzumab treatment. In 
NeoALTTO, high tumor p95 content correlated with a benefit of adding lapatinib to 
trastuzumab; tumors with high p95 expression also had the highest HER2 expression [13]. As 
new HER2-targeting TKI’s emerge, such as tucatinib and neratinib, further investigations 
exploring the utility of quantitative p95 and HER2 expression as predictive indicators of 
response to dual HER-2 directed therapy are warranted. 
We note that the size of the subset of patients with HER2-positive cancer was relatively small 
in the FinHer trial, thus limiting the statistical power of this study. Despite this limitation, we 
found a statistically significant association between tumor p95 content and DDFS, suggesting 
that the oncogenic impact of p95 expression is strong. In the FinHer trial, trastuzumab 
administration was limited to 9 weeks concomitant with chemotherapy, while the current 
standard duration of trastuzumab administration is 12 months. Therefore, further study is 
warranted to investigate the predictive correlations between tumor p95 expression levels and 
survival in a setting where adjuvant trastuzumab is administered for a longer duration. 
In summary, we conclude that patients with high breast tumor p95 levels experience 
unfavorable clinical outcomes relative to patients with low tumor p95 levels when the patients 
are treated with surgery and adjuvant chemotherapy, but not when the systemic treatment 
includes trastuzumab. This finding suggests that high tumor p95 content is a predictive 
biomarker for the efficacy of adjuvant trastuzumab. 
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Figure Legends: 
Figure 1. p95 and HER2 distributions according to hormone receptor status. HER2 reference 
lines (dashed lines) correspond to HERmark negative, equivocal and positive analytical cutoffs. 
The p95 reference line is the prognostic clinical cutoff for trastuzumab-treated metastatic breast 
cancer [8, 9]. HER2 protein expression by hormone receptor status (A). p95 HER2 protein 
expression by hormone receptor status (B). p95 versus HER2 expression in the HR-negative 
subset (C). p95 versus HER2 expression in the HR-positive subset (D). The solid boxes denote 
the median and the upper and the lower quartiles. 
Figure 2. Kaplan-Meier plots of DDFS by adjuvant treatment containing versus not containing 
trastuzumab for p95-negative tumors (A) and p95-positive tumors (B). 
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Table 1. Patient characteristics 
Characteristic Category N % 
HER2 CISH positive 192 100 
Central HER2 IHC 
retest 
3+ 
2+ 
1+ 
0 
126 
53 
9 
4 
66 
28 
5 
2 
HER2 proteina 
positive 
equivocal 
negative 
154 
14 
24 
80 
7 
13 
p95 proteina 
positive 
negative 
86 
106 
45 
55 
ER 
positive 
negative 
93 
99 
48 
52 
PR 
positive 
negative 
67 
125 
35 
65 
Hormone receptorb 
positive 
negative 
98 
94 
51 
49 
Adjuvant trastuzumab 
administered 
yes 
no 
97 
95 
51 
49 
HER2, human epidermal growth factor receptor 2, CISH, 
chromogenic in situ hybridization; ER, estrogen 
receptor;; PR, progesterone receptor
a Cutoffs of 10.5 and 17.8 for the HERmark HER2 assay and 
2.8 for the p95 assays were applied as described in the 
Methods section. 
b Hormone receptor positive status was defined as either ER or 
PR positive. 
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Table 2. Associations between breast cancer HER2 and p95 content with DDFS in univariable 
survival analyses 
Treatment arm and variable HRa P-value 
Chemotherapy Alone 
Log10 (HER2) 1.2  .30 
Log10 (p95) 2.0  .02 
Chemotherapy + trastuzumab 
Log10 (HER2) 0.98  .93 
Log10 (p95) 0.58  .19 
HER2, human epidermal growth factor receptor 2; HR, hazard 
ratio 
Stratification was by cancer hormone receptor status, nodal 
status and chemotherapy type 
a Hazard ratios for 2-fold change in log10 (HER2) or log10 (p95) 
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Table 3. Multivariable predictive models for DDFS 
 HER2 model p95 model 
Variable   HR P-value   HR P-value 
Node positive cancer   5.2  .03   6.3  .01 
Vinorelbine-containing 
chemotherapy 
  1.8  .06   1.8  .07 
ER and/or PR positive 
cancer 
  0.76  .38   0.76  .38 
Trastuzumab administered   0.53  .04   0.55  .06 
Log10 (HER2)
 a   1.6  .27   NC   NC 
Log10 (HER2) : trastuzumab 
interaction a 
  0.58  .35   NC   NC 
Log10 (p95)
 a   NC  NC   5.0  .01 
Log10 (p95) : trastuzumab 
interaction a 
  NC  NC   0.06  .01 
HR, hazard ratio; ER, estrogen receptor; PR, progesterone 
receptor; NC, not considered. 
a Hazard ratios for 2-fold change in log10 (HER2) or log10 (p95) 
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Table 4. Multivariable predictive models of p95 for DDFS in subsets of patients defined by 
breast cancer steroid hormone receptor expression 
Hormone  
receptor   
negative 
Hormone 
receptor 
positive 
Variable   HR P-value   HR P-value 
Node positive    --a  1   1.1  .93 
Vinorelbine-containing 
chemotherapy 
  1.7  .26   1.8  .26 
Trastuzumab administered   0.98  .98   0.47  .14 
Log10 (p95)
 b   19.7  .009   1.3  .81 
Log10 (p95) : trastuzumab 
interaction b 
  0.002  .009   0.79  .90 
HR, hazard ratio
a Estimate of hazard ratio could not be determined due to a low 
number of node positive patients
b Hazard ratios for 2-fold change in log10 (p95) 


